According to latest market data, DCB Bank, Surana Solar and Srinibas Pradhan Constructions emerged as the strongest momentum stocks on July 27, 2026, with sustained buying interest driving significant gains. DCB Bank advanced 6.36% to ₹198.75, trading above all key moving averages including the 30-day SMA of ₹186.87, 50-day SMA of ₹183.25, 150-day SMA of ₹182.41 and 200-day SMA of ₹177.18. Surana Solar rose 9.92% to ₹29.13, closing above its 30-day SMA of ₹26.50, 50-day SMA of ₹26.60, 150-day SMA of ₹25.31 and 200-day SMA of ₹26.62. Srinibas Pradhan Constructions gained 8.26% to ₹146.50, remaining above its 30-day SMA of ₹135.32 and 50-day SMA of ₹134.89 throughout the session.
According to reports from Business Standard, Kotak Securities has recommended DCB Bank as a BUY with a current market price of ₹191 against a face value of ₹225. The bank is positioned as a niche private sector lender with a well-diversified, predominantly secured lending franchise focused on retail, MSME and agriculture segments. DCB's loan book is anchored by mortgages (39% of advances), agriculture (24%), corporate loans (8%), MSME/SME (8%), and other retail products including gold loans. The bank reported healthy 1QFY27 earnings growth of 35% YoY, driven by sharp decline in credit costs, while maintaining robust loan growth of 17% YoY and stable NIMs of 3.4%.
According to latest financial results, Dr Lal Path Labs delivered exceptional Q1FY27 performance with consolidated net profit surging 27.2% to ₹1,705 crore for the quarter ended June 30, 2026. The diagnostics company's total income from operations rose 18.9% to ₹8,296 crore, while EBITDA grew 28.7% to ₹2,564 crore with margins improving to 30.9% from 28.7% in the previous year. The growth was primarily volume-driven, with sample volumes increasing 10.7% year-on-year and patient volumes rising 8.2%. As of March 31, 2026, the company operated 312 clinical laboratories, 7,727 Patient Service Centers and 13,935 Pick-up Points, servicing over 1 lakh patients through its rural outreach program in seven states during the quarter.
As reported by Business Standard, asset quality remained resilient with GNPA/NNPA at 2.4%/0.8%, despite temporary rise in gold loan slippages. Management remains confident of maintaining GNPA below 2.5% and NNPA below 1% supported by conservative underwriting standards. The bank expects loan and deposit CAGR of ~19-20% over FY26-29E, supported by improving operating leverage and stable funding profile. Growth visibility remains healthy with gold loans growing 125% YoY, while mortgage originations focus on higher-ticket, self-sourced customers.
As reported by Business Standard, growth continues to be driven by structural factors including rising awareness around preventive healthcare and increasing incidence of lifestyle diseases. The company is expanding its presence in smaller towns through rural outreach programme while Suburban Diagnostics improves performance in western India. International expansion has begun with incorporation of wholly owned subsidiary in Dubai, while management expects mid-teen revenue growth in FY27. The company maintains strong cash generation, high return ratios and debt-free balance sheet, allowing investment in network expansion.
According to Business Standard, DCB Bank continues to trade at attractive valuations of 0.9x FY27E P/BV with return ratios expected to improve steadily. RoE is projected to rise from 12.0% in FY26 to 13.3% in FY27E and 14.4% in FY28E, while earnings are projected to grow at nearly 20% CAGR. Dr Lal Path Labs maintains a fair value of ₹2,030 with strong cash generation and debt-free balance sheet supporting continued investment in network expansion. The company declared an interim dividend of ₹5 per share payable to shareholders on record by July 30, 2026.
